Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iressa Maintenance in Stage III NSCLC
NCT00234468Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Jan 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefitinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Jan 2004; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00234468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00234468.